Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St set for mixed open ahead of SK Hynix listing; Middle East in focus
- Oil heads for weekly gains as Middle East supply risks persist
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
Vanda Pharmaceuticals (VNDA) PT Raised to $27 at Oppenheimer, 'Near-term Stock Set-up Remains Solid'
February 15, 2018 6:48 AM ESTOppenheimer raised its price target on Vanda Pharmaceuticals (NASDAQ: VNDA) to $27.00 (from $25.00) while maintaining a Outperform rating.
... More